Methods: MEDLINE/PUBMED, The Cochrane Library, Clinical Trials, SciELO and LILACS were searched for studies published until December 2014. Included articles were: prospective studies; including patients older than 18 years, diagnosed with periodontitis and rheumatoid arthritis submitted to non-surgical periodontal treatment; with a control group receiving no periodontal treatment; with outcomes including at least one marker of rheumatoid arthritis activity. Methodological quality of the studies was assessed using PEDro scale. Quantitative data were pooled in statistical meta-analysis using Review Manager 5.
Introduction
Previous clinical and experimental studies have suggested an association between periodontal disease (PD) and rheumatoid arthritis (RA). [1] [2] [3] [4] [5] [6] [7] [8] [9] This association is based on common environmental, inflammatory and genetic pathways shared by RA and PD that include smoking, HLA-DR antigens, inflammatory pattern, tissue destruction pathways. Furthermore, the possible role of periodontopathic bacteria Porphyromonas gingivalis, that produces a peptidylarginine deiminase capable of citrullination of human proteins, was demonstrated in RA. A possible role for PD in hampering anti-tumor necrosis factor treatment response in RA has also been suggested. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] A series of intervention trials to assess the effect of PD treatment on RA have been performed. These trials examined different RA activity parameters, such as Disease Activity Score (DAS 28), erythrocyte sedimentation rate (ESR), Creactive protein (CRP), patient's assessment of rheumatoid activity using visual analogical scale (VAS), tender (TJC) and swollen (SJC) joint counts, cytokines (Interleukin (IL) 1-␤, tumor necrosis factor (TNF)-␣), antibodies (rheumatoid factor, anti-cyclic citrullinated protein antibodies, antibodies anti-P. gingivalis) and/or measures of quality of life. The results were quite controversial, with positive, negative or neutral findings regarding the effect of PD treatment on RA outcomes. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Therefore, the impact of PD treatment on RA activity remains to be determined.
The present systematic review and meta-analysis aimed to investigate the effects of PD non-surgical treatment in inflammatory parameters and clinical measures of RA activity in adult patients. This review was conducted according to the QUOROM statement for improving the quality of reports of meta-analyses of randomized controlled trials. 32 
Methods

Search strategy
The bibliographical databases MEDLINE/PUBMED, The Cochrane Library, Clinical Trials, SciELO and LILACS were searched for all published studies, from the beginning of the database, until December 2014, without language restrictions.
The search strategy for MEDLINE/PUBMED, The Cochrane Library and Clinical Trials databases was: ((Chronic Periodontitides) OR (Periodontitides, Chronic) OR (Periodontitis, Chronic) OR (Adult Periodontitis) OR (Adult Periodontitides) OR (Periodontitides, Adult) OR (Periodontitis, Adult)) AND ((Rheumatoid arthritis) OR (Arthritis, rheumatoid)). The search strategy for LILACS and SciELO was: ((Chronic Periodontitis) OR (Periodontitis Crónica) OR (Periodontite Crônica)) AND ((Arthritis, Rheumatoid) OR (Artritis Reumatoide) OR (Artrite Reumatoide)).
The search was independently performed by two reviewers (DCC, JDC). Disagreements were solved by discussion. The Kappa between the two reviewers that independently performed the search was 0.764.
In addition to the online search, a hand search of the bibliographies of reviews, comments, letters, case reports, editorials and other papers addressing the relationship between RA and PD was conducted.
The flowchart of the search and selection process is shown in Fig. 1 .
Methodological quality of the included studies was assessed using the PEDro scale 33 by two independent reviewers (DCC and JDC) and disagreements were solved through discussion.
Selection criteria
Inclusion criteria
Intervention studies; inclusion of adult patients (older than 18 years) diagnosed with both PD and RA; intervention comprised of non-surgical periodontal treatment; presence of a control group receiving no periodontal treatment for the length of the study; outcome for RA that included at least one of the following: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Disease Activity Score (DAS28), tender (TJC) and swollen (SJC) joint counts and patient's assessment of RA activity using a 100 mm-visual analogical scale (VAS); follow-up of at least six 6 weeks.
Exclusion criteria
Case reports, review articles, editorials, comments, letters to the editor, experimental studies/basic science, articles on RA therapeutic interventions and reports about patients with rheumatic diseases other than RA were excluded.
Data collection
Data abstraction was performed in duplicate, by two independent reviewers (DCC, JDC). Attempts were made to contact original authors for missing data, but only the authors of one article provided us the information required (TJC and SJC mean and standard deviation in periodontal disease for treated and non-treated groups at baseline and after follow-up). 29 
Methodological quality assessment
The quality of the studies was peer-reviewed (DCC, JDC) by using a modified version of the PEDro scale for clinical trials. 33 Disagreements were resolved by consensus (Table 1) .
Quantitative data synthesis
Quantitative data were pooled in statistical meta-analysis using Review Manager (RevMan) 5. To assess overall efficacy from all the studies included in the meta-analysis, we calculated mean difference using both fixed-effects and random-effects models, reporting heterogeneity and overall p-values. When I 2 > 50% indicated high heterogeneity between studies, the random-effect model was adopted, and when I 2 < 50% the fixed effect model was used. Studies that did not report standard deviation were excluded from the meta-analysis. The effect sizes for each study and overall pooled effect sizes were calculated with a 95% confidence interval. Statistical significance was declared if the p value was less than 0.05.
Results
Four articles [25] [26] [27] 29 were included in the meta-analysis (Table 2) .
They were single-center interventional controlled studies. The criteria used for the diagnosis of periodontitis varied. Al-Katma et al. 25 included patients with generalized mildto-moderate chronic periodontitis according to Armitage 35 ; Pinho et al. 26 defined PD according to Machtei et al. 36 : the presence of at least two teeth with CAL ≥ 6 mm and at least one tooth with probing depth ≥ 5 mm. Ortiz et al. 27 included patients with generalized severe chronic periodontitis according to Löe and Sillness, 37 while Okada et al. 29 defined periodontitis as the presence of at least one site with CAL ≥ 4 mm.
Studies were conducted from 2007 to 2013 in different countries: Brazil, 26 Japan 29 and USA 25, 27 with participants from different ethnic and cultural backgrounds.
Subjects of these studies presented both RA and PD, and were divided in two groups: one submitted to non-surgical periodontal treatment consisting of scaling/root planning and plaque removal and hygiene instructions (treatment group) and one other group that was only followed up during the period of the study (control group), without periodontal treatment or oral hygiene instruction.
The follow-up period was 6-weeks, 25 8-weeks 27, 29 or six months. 26 PEDro scores of the studies included in this meta-analysis are shown in Table 1 . Quality assessment varied from 7 to 5 points.
Analysis of the pooled data for the outcomes evaluated on this meta-analysis is shown in Table 3 .
DAS28 is a composite disease activity score that has been largely used to measure RA activity. 38 A reduction of DAS 28 means that RA has improved. The pooled data of the two studies included in the meta-analysis suggests a discrete, but significant reduction in DAS 28 score following non-surgical periodontal treatment (OR: −1.18; 95% CI: −1.43, −0.93; p < 0.00001) ( Table 3 ; Fig. 2 ). 25, 27 There was no evidence for an effect of periodontal therapy in the blood levels of CRP (OR: −0. (Table 3) . 25, 26, 29 
Discussion
RA and PD share similar pathogenic mechanisms, i.e. inflammatory cells and pro-inflammatory cytokines that drive chronic bone erosion in RA and chronic gum destruction in PD are similar. A role for PD on initiation and maintenance of RA autoimmune inflammatory responses, even in RA patients receiving conventional synthetic disease modifying anti-rheumatic drugs or biologics (specifically TNF inhibitors), has been suggested. 6, 10, [12] [13] [14] [15] 21 The control of local periodontal infection and inflammation by non-surgical periodontal therapy is expected to attenuate systemic inflammatory response which in turn would contribute to improve RA activity. Accordingly, the current meta-analysis shows that, after non-surgical periodontal treatment, there is reduction of DAS28 in RA patients with PD, corroborating the impact of periodontal condition on RA.
In contrast, evaluation of the other variables failed to demonstrate the effect of PD treatment in RA activity. A possible explanation is regarding the complex nature of RA, which disease activity is better evaluated by a composite score like DAS28 instead of individual analysis of inflammatory and clinical markers.
Corroborating these findings, recently, Kaur et al. 22 published a systematic review on the association between PD and RA. The periodontal parameter clinical attachment level (CAL) was greater in patients with RA than in subjects without RA, indicating that PD may be more severe in RA. RA patients also had increased tooth loss when compared to non-RA patients. In line with these findings, some biochemical RA, rheumatoid arthritis; P, periodontitis; DAS 28, disease activity score; DAS28-CRP, disease activity score using C-reactive protein; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; TJC, tender joint count; SJC, swollen joint count; VAS, visual analogical scale; IS, intervention study; C, controlled; R, randomized; U, unicentric; RND, randomization not described; B, blinded; BND, blinding not described; Wk, weeks; Mo, months. a Rheumatologist blinded to periodontal treatment. Patients: those submitted to non-surgical periodontal treatment. Controls: Those not submitted to periodontal treatment. b Four: absence to evaluations; three: changes in medications for RA. c One: absence to evaluations; one: inability to maintain good level of oral hygiene. markers were increased in RA patients with PD (CRP, IL-1␤ and serum antibodies to P. gingivalis), in comparison with patients without PD. Although, no differences in other parameters (ESR, anti-cyclic citrullinated protein antibodies, rheumatoid factor, TNF-␣) were observed comparing both groups, a trend toward a decrease in ESR in RA patients after PD treatment was reported. 22 In another systematic review with meta-analysis, Kaur et al. 23 have also evaluated the influence of PD treatment on RA activity. In their pooled data meta-analysis, DAS28 was not influenced by PD non-surgical therapy. Kaur et al. 23 included, in the pooled meta-analysis of DAS28, the data from the study of Okada et al., 29 that analyzed DAS28-CRP, another RA activity composite score, slightly different from DAS28 (instead of ESR, it includes CRP), that presents good correlation, but underestimates disease activity when compared to DAS28. 39 For this reason, the results of Kaur et al. 23 might have biased the possible influence of PD treatment on DAS28 and in the present meta-analysis, the data on DAS28-CRP were excluded from the analysis. They have also found a significant reduction of ESR in PD treated patients, what might be explained through the inclusion of the data from Ortiz et al., 27 since Kaur et al. 23 transformed inter-quartile ranges or ranges in standardized mean difference, assuming a normal distribution curve for this study, increasing the number of patients and improving the detection of small differences.
The four studies eligible for this meta-analysis evaluated a small number of subjects. Randomization was well described in one, 25 cited in two 27, 29 and not mentioned in one. 26 Regarding PD treatment, blinding of patients and therapists, is not possible. To overcome this limitation, one alternative is blinding the evaluator. This was mentioned in only one study. 25 One study 25 had a high number of dropouts. Participants had PD diagnosed according to different classification systems. The follow-up period ranged from 6-weeks to 8-weeks in three studies, 25, 27, 29 which is a relatively short time to assess the impact of therapeutic strategies in RA activity. All studies reported an objective improvement in periodontal clinical parameters, suggesting that the follow-up period was sufficient to observe reduction in infection and inflammation associated with PD. The heterogeneity among studies was high for most outcomes evaluated. These features must be weighted as possible limitations of the present meta-analysis.
The current meta-analysis suggests that non-surgical periodontal treatment might have a beneficial effect on RA activity as evaluated by DAS28. Further randomized controlled clinical trials including a larger number of patients, with appropriate blinding and longer periods of follow-up are necessary to confirm this finding.
